Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

947 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis.
Jairath V, Zou GY, Parker CE, MacDonald JK, AlAmeel T, Al Beshir M, Almadi MA, Al-Taweel T, Atkinson NS, Biswas S, Chapman T, Dulai PS, Glaire MA, Hoekman DR, Koutsoumpas A, Minas E, Mosli MH, Samaan M, Khanna R, Travis S, D'Haens G, Sandborn WJ, Feagan BG. Jairath V, et al. Among authors: sandborn wj. Cochrane Database Syst Rev. 2017 Sep 8;9(9):CD011572. doi: 10.1002/14651858.CD011572.pub2. Cochrane Database Syst Rev. 2017. PMID: 28886205 Free PMC article. Review.
The effectiveness of budesonide therapy for Crohn's disease.
Kane SV, Schoenfeld P, Sandborn WJ, Tremaine W, Hofer T, Feagan BG. Kane SV, et al. Among authors: sandborn wj. Aliment Pharmacol Ther. 2002 Aug;16(8):1509-17. doi: 10.1046/j.1365-2036.2002.01289.x. Aliment Pharmacol Ther. 2002. PMID: 12182751 Free article. Review.
A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease.
Feagan BG, Sandborn WJ, Baker JP, Cominelli F, Sutherland LR, Elson CO, Salzberg BA, Archambault A, Bernstein CN, Lichtenstein GR, Heath PK, Cameron S, Hanauer SB. Feagan BG, et al. Among authors: sandborn wj. Aliment Pharmacol Ther. 2005 Feb 15;21(4):373-84. doi: 10.1111/j.1365-2036.2005.02336.x. Aliment Pharmacol Ther. 2005. PMID: 15709987 Free article. Clinical Trial.
Natalizumab induction and maintenance therapy for Crohn's disease.
Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S, Goldblum R, Despain D, Hogge GS, Rutgeerts P; International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. Sandborn WJ, et al. N Engl J Med. 2005 Nov 3;353(18):1912-25. doi: 10.1056/NEJMoa043335. N Engl J Med. 2005. PMID: 16267322 Free article. Clinical Trial.
947 results